PADCEV is a Nectin-4-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of Padcev (enfortumab vedotin-ejfv) brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the Padcev enfortumab vedotin-ejfv medicine cost price in India.
The order for Padcev (enfortumab vedotin-ejfv) will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
In December 2019, enfortumab vedotin-ejfv was approved in the United States for the treatment of adult patients with locally advanced or metastatic urothelial cancer who had previously received a programmed cell death receptor-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy.
PADCEV (enfortumab vedotin-ejfv) for injection, for intravenous use Initial U.S. Approval: 2019
Generic Name: enfortumab vedotin-ejfv
For Injection: 20 mg and 30 mg of enfortumab vedotin-ejfv as a lyophilized powder in a single-dose vial for reconstitution
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Padcev (enfortumab vedotin-ejfv) on prescription and Import License in Patient's Name only.
For overseas patients, Padcev (enfortumab vedotin-ejfv) can be made available in Send your enquiry to find Padcev (enfortumab vedotin-ejfv) in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For Padcev (enfortumab vedotin-ejfv) Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer For More Details
Enfortumab Vedotin + Pembrolizumab Shrink Tumors in the Majority of Bladder Cancer Patients For More Details